Cargando…
Clinical application of PARP inhibitors in ovarian cancer: from molecular mechanisms to the current status
As a kind of gynecological tumor, ovarian cancer is not as common as cervical cancer and breast cancer, but its malignant degree is higher. Despite the increasingly mature treatment of ovarian cancer, the five-year survival rate of patients is still less than 50%. Based on the concept of synthetic l...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9826575/ https://www.ncbi.nlm.nih.gov/pubmed/36611214 http://dx.doi.org/10.1186/s13048-023-01094-5 |